Arcus Biosciences Net Profit Margin 2017-2023 | RCUS
Arcus Biosciences net profit margin from 2017 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Arcus Biosciences Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2023-03-31 |
$0.12B |
$-0.28B |
-232.50% |
| 2022-12-31 |
$0.11B |
$-0.27B |
-236.28% |
| 2022-09-30 |
$0.43B |
$0.08B |
18.43% |
| 2022-06-30 |
$0.41B |
$0.07B |
16.38% |
| 2022-03-31 |
$0.39B |
$0.06B |
14.83% |
| 2021-12-31 |
$0.38B |
$0.05B |
13.87% |
| 2021-09-30 |
$0.04B |
$-0.28B |
-754.05% |
| 2021-06-30 |
$0.09B |
$-0.20B |
-213.98% |
| 2021-03-31 |
$0.09B |
$-0.17B |
-195.35% |
| 2020-12-31 |
$0.08B |
$-0.12B |
-155.70% |
| 2020-09-30 |
$0.08B |
$-0.09B |
-111.39% |
| 2020-06-30 |
$0.02B |
$-0.11B |
-700.00% |
| 2020-03-31 |
$0.02B |
$-0.10B |
-593.75% |
| 2019-12-31 |
$0.02B |
$-0.09B |
-531.25% |
| 2019-09-30 |
$0.01B |
$-0.08B |
-1000.00% |
| 2019-06-30 |
$0.01B |
$-0.07B |
-690.00% |
| 2019-03-31 |
$0.01B |
$-0.06B |
-611.11% |
| 2018-12-31 |
$0.01B |
$-0.05B |
-625.00% |
| 2018-09-30 |
$0.01B |
$-0.05B |
-728.57% |
| 2018-06-30 |
$0.00B |
$-0.06B |
-2100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.582B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
